Integrative multi-omics analysis identifies an enhancer-driven ELF3-CLDN4 regulatory axis that shapes an immunosuppressive microenvironment and predicts prognosis in high-grade serous ovarian cancer.
Aug 2026· Gene· pp.
150360
· 0 citations· 52 references
Medicine
TL;DR
An enhancer-associated ELF3-CLDN4 axis links tumor-cell regulatory plasticity with CD4⁺ T-cell immunosuppression and adverse prognosis in HGSOC.
Abstract
Objectives
High-grade serous ovarian cancer (HGSOC) is marked by genomic instability, immune suppression, and poor outcome, yet enhancer-gene networks coordinating malignant epithelial programs and CD4⁺ T-cell states remain unclear. We aimed to identify enhancer-associated regulatory circuits linking tumor plasticity, CD4⁺ T-cell polarization, and prognosis in HGSOC.
Methods
We integrated H3K27ac ChIP-seq, Hi-C, single-cell RNA-seq, spatial transcriptomics, TCGA-OV data, CD4⁺ T-cell eQTLs, and pharmacogenomic annotations to reconstruct cell-type-specific enhancer-gene regulatory networks. Motif enrichment, SCENIC, Louvain clustering, CellChat, pseudotime analysis, spatial deconvolution, GSVA, and survival modeling were applied. Seven-color multiplex immunofluorescence was performed in 90 primary HGSOC and 10 non-malignant ovarian tissues.
Results
HGSOC showed redistribution of H3K27ac signals toward distal regulatory regions linked to immune and tumor-cell programs. Single-cell profiling identified an aneuploid malignant epithelial compartment and a Treg-skewed CD4⁺ T-cell landscape. Integrated network analysis highlighted ELF3, FLI1, KLF4, and ZNF250 as shared hub transcription factors. Among these, an ELF3-associated enhancer-CLDN4 axis was supported by chromatin contacts and CD4⁺ T-cell eQTL evidence. eGRN-active CD4⁺ Th17 cells showed altered communication patterns, aberrant pseudotime positioning, and preferential peritumoral localization, particularly in JAK1-high spatial samples, where they co-localized with Tregs and macrophages. Multiplex immunofluorescence confirmed elevated ELF3 and CLDN4 expression in HGSOC, positive associations with Treg accumulation, inverse associations with Th17 infiltration, and correlations with poor overall survival. ELF3-high and CLDN4-high status remained independent adverse prognostic factors.
Conclusions
An enhancer-associated ELF3-CLDN4 axis links tumor-cell regulatory plasticity with CD4⁺ T-cell immunosuppression and adverse prognosis in HGSOC.
Background and Objectives: LHFPL5 encodes a four-pass transmembrane protein essential for cochlear mechanotransduction, but its molecular behavior in cancer remains poorly defined. We characterized the genomic, epigenetic, transcriptomic, immune, and cellular context of LHFPL5 in clear cell renal cell carcinoma (KIRC)...
Hakeemah H. Al-Nakhle, Zinab O. Doha· Medicina· 0 citations
This study established an integrative strategy enabling high confidence cell identity assignment in sparse epigenomic data, and revealed the roles of B cell subtypes in the regulation of tumor immunity.
Chen-Yu Wang, Qi-Xin Hu, Jian Chen et al.· The Innovation Oncology· 0 citations
The PLK1/FOXM1-associated tumor-cell state may represent a distinct molecular feature associated with proliferative activity, invasive phenotypes, and macrophage-related immune features in EC and is highlighted in potential therapeutic directions for future investigation.
Long-Wei Li, Yun-yun Xiao, Ya-Ping Wang et al.· Frontiers in Oncology· 0 citations
Cholangiocarcinoma (CHOL) is a highly heterogeneous and aggressive malignancy that is frequently diagnosed at an advanced stage because of the lack of early biomarkers, resulting in a poor prognosis. Although ANAPC1 overexpression has been reported in other cancers, its role and regulatory mechanisms in CHOL rema...
Ke-Jun Wu, Lei Wang, Yan-Ting Zhan et al.· Hereditas· 0 citations
These findings identify CDC20 as a recurrence-associated molecular node involved in BaP-responsive malignant biological phenotypes and provide a phenotype-anchored framework linking recurrence biology with environmental exposure-related tumor behavior.
Xu-Chao Dai, Wei Gu, Bo Yu et al.· Frontiers in Cell and Develo...· 0 citations
MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.
Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al.· Cancer Genomics & Proteomics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.